Treace Medical Showcases Innovations at Major Foot and Ankle Meeting

Treace Medical Innovations Revealed at AOFAS Annual Meeting

PONTE VEDRA, Fla. – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI), known for transforming the surgical treatment of bunions and midfoot deformities, recently made waves during the annual AOFAS meeting. At this prestigious event, Treace showcased new product innovations and interim data from ongoing clinical studies.

Exciting Developments in Clinical Studies

During the conference, Treace highlighted significant findings from their clinical studies. CEO John T. Treace expressed enthusiasm for presenting these updates to the attending surgeons. The ongoing ALIGN3D™ clinical study revealed that patients experienced consistent and effective procedural outcomes well into the 3 and 4-year marks post-surgery. Furthermore, interim findings from the Mini3D™ Lapiplasty® Mini-Incision™ clinical study showcased positive results at the 1 and 2-year follow-ups.

Industry-Leading Innovations

Treace is recognized as the only company dedicated solely to enhancing surgical corrections for bunions and related deformities. Mr. Treace elaborated on their commitment to developing advanced solutions that cater to surgeons' evolving needs and preferences.

Featured Products at AOFAS Conference

Several exciting technologies caught the attention of attendees at Treace's booth, including:

• Nanoplasty™ MIS 3D Osteotomy System: With a discreet 1.5 cm incision, this system is designed for aesthetic considerations while minimizing post-operative pain and swelling. It marks Treace's entry into the osteotomy domain, which is crucial in bunion surgeries.
• IntelliGuide™ PSI Cut Guides: This innovative cutting guide utilizes patient CT scans for custom surgical planning, enabling a seamless correction procedure.
• Mini-Adductoplasty™ Guides: Aimed at providing surgeons a less invasive option, these guides facilitate midfoot correction with a smaller incision.
• New SpeedPlate™ Innovations: Newly introduced designs enhancing stability and fit for midfoot and rearfoot fusions.
• Micro-Lapiplasty™ System: This system provides an advanced method to perform the procedure via a small incision, enhancing patient recovery.

Clinical Study Presentations at AOFAS

The presentations at AOFAS included significant data from the ALIGN3D™ clinical study, led by Dr. Robert Santrock from Duke University. Key insights indicated:

• Patients returned to weight-bearing activity in a walking boot within an average of 8.4 days.
• Radiographic recurrence rates were impressively low, with a 0.0% recurrence at the 48-month mark.
• Patient-reported outcomes indicated continued pain relief and enhanced quality of life over time.

Mini3D™ Lapiplasty Mini-Incision™ Study Insights

In addition to the ALIGN3D™ study, interim findings from the Mini3D™ study presented by Dr. Justin Daigre also received acclaim. The data showcased favorable outcomes from patients undergoing the Mini-Incision™ Procedure, confirming the procedure's efficacy.

The Importance of Treace's Innovations

Treace's contributions are pivotal in addressing the significant need for effective bunion treatments in the United States, where approximately 67 million Americans are affected by bunions. The Company emphasizes its innovative approach through techniques designed to address these complex deformities comprehensively.

Learn More About Treace Medical

To discover Treace's range of products and innovative solutions, visit their official website. Knowledge about their advancements significantly benefits surgeons and enhances patient outcomes in bunion and midfoot surgeries.

Frequently Asked Questions

What is the ALIGN3D™ clinical study?

The ALIGN3D™ study evaluates the effectiveness of the Lapiplasty® procedure for bunion surgery, focusing on long-term patient outcomes and radiographic results.

What innovations did Treace present at AOFAS?

Treace showcased several new products, including the Nanoplasty™ 3D Osteotomy System, IntelliGuide™ PSI, and new SpeedPlate™ innovations designed to enhance surgical procedures.

What were the outcomes of the Mini3D™ study?

The Mini3D™ study reported positive patient outcomes and effective results from the Mini-Incision™ System at 1 and 2 years after surgery.

Why are Treace’s products significant for bunion treatment?

Treace's products focus on minimally invasive techniques, aiming to deliver effective solutions that improve recovery times and surgical outcomes for patients with bunions.

Where can I find more information about Treace Medical Concepts?

For comprehensive details, including latest innovations and clinical data, you can visit Treace's official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.